AR075122A1 - Derivados de piridazinona - Google Patents
Derivados de piridazinonaInfo
- Publication number
- AR075122A1 AR075122A1 ARP100100014A ARP100100014A AR075122A1 AR 075122 A1 AR075122 A1 AR 075122A1 AR P100100014 A ARP100100014 A AR P100100014A AR P100100014 A ARP100100014 A AR P100100014A AR 075122 A1 AR075122 A1 AR 075122A1
- Authority
- AR
- Argentina
- Prior art keywords
- nhet
- nhet1
- atoms
- hal
- het1
- Prior art date
Links
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000972349 Ocoa Species 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de la formula (1) en donde D es un heterociclo insaturado o aromático de cinco o seis miembros con 1 a 3 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal y/o A, R1 es OH, OA, O[C(R5)2]nAr, O[C(R5)2]nHet, O[C(R5)2]pN(R5)2, N(R5)2, NR5[C(R5)2]nAr, NR5[C(R5)2]nHet, NR5[C(R5)2]pN(R5)2, COOR5, CON(R5)2, CONR5[C(R5)2]pN(R5)2, CONR5[C(R5)2]pOR5, CONR5[C(R5)2]nHet, COHet o COA, R2 es H, A, Hal, OH, OA, N(R5)2, N=CR5N(R5)2, SR5, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, SO2N(R5)2, S(O)mA, [C(R5)2]nN(R5)2, [C(R5)2]nHet, O[C(R5)2]pN(R5)2, O[C(R5)2]nHet, S[C(R5)2]pN(R5)2, S[C(R5)2]nHet, NR5[C(R5)2]pN(R5)2, -NR5[C(R5)2]nHet, NHCON(R5)2, NHCONH[C(R5)2]pN(R5)2, NHCONH[C(R5)2]nHet, NHCO[C(R5)2]pN(R5)2, NHCO[C(R5)2]nHet, CON(R5)2, CONR[C(R5)2]pN(R5)2, CONR5[C(R52]nHet, COHet, COA, O[C(R5)2]nNR5COZ, O[C(R5)2]nNR2COHet1, O[C(R5)2]nCyc[C(R5)2]nN(R5)2, O[C(R5)2]nCyc[C(R5)2]nOR5, O[C(R5)2]nCyc[C(R5)2]nHet1, O[C(R5)2]n-C(CH2-(CH2)q)-[C(R5)2]nN(R5)2, O[C(R5)2]n-C(CH2-(CH2)q)-[C(R5)2]nOR5, O[C(R5)2]n-C(CH2)-(CH2)q)-[C(R5)2]nHet, O[C(R5)2]nCR5(NR5)2COOR5, O[C(R5)2]nNR5CO[C(R5)2]nNR5COA, O[C(R5)2]nNR5COOA, O[C(R5)2]nCO-NR5-A, O[C(R5)2]nCO-NR5-[C(R5)2]nHet1, O[C(R5)2]nCONH2, O[C(R5)2]nCONHA, O[C(R5)2]nCONA2, O[C(R5)2]nCO-NR5-[C(R2)2]nN(R5)2 u OCOA; Z es CR5(NR5)2CR5(OR5)A; R3 es H o A; R4 es H, A o Hal, R5 es H o A'; A es alquilo no ramificado o ramificado con 1-10 átomos de C, en donde 1-7 átomos de H pueden estar reemplazados por OH, F, CI y/o Br, y/o en donde uno o dos grupos CH2 pueden estar reemplazados por O, NH, S, SO, SO2 y/o grupos CH=CH, o es alquilo cíclico con 3-7 átomos de C, en donde 1-7 átomos de H pueden estar reemplazados por OH, F, CI y/o Br, A' es alquilo no ramificado o ramificado con 1-6 átomos de C, en donde 1-5 átomos de H pueden estar reemplazados por F, Cyc es cicloalquileno con 3-7 átomos de C, Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di- o trisustituido con Hal, A, OR5, N(R5)2, SR5, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, SO2N(R5)2, S(O)mA, CO-Het1, [C(R5)2]nN(R5)2, [C(R5)2]nHet1, O[C(R5)2]pN(R5)2, O[C(R5)2]nHet1, NHCOOA, NHCON(R5)2, NHCOO[C(R5)2]pN(R5)2, NHCOO[C(R5)2]nHet1, NHCONH[C(R5)2]pN(R5)2, NHCONH[C(R5)2]Het1, OCONH(C(R5)2]pN(R5)2 y/u OCONH[C(R5)2]nHet1, Het es un heterociclo mono-, bi- o tricíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OR5, N(R5)2, SR5, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, SO2N(R5)2, S(O)mA, CO-Het1, [C(R5)2]nN(R5)2, [C(R5)2]nHet1, O[C(R5)2]pN(R5)2, O[C(R5)2]nHet1, NHCOOA, NHCON(R5)2, NHCOO[C(R5)2]pN(R5)2, NHCOO[C(R5)2]nHet1, NHCONH[C(R5)2]pN(R5)2, NHCONH[C(R5)2]Het1, OCONH(C(R5)2]pN(R5)2 OCONH[C(R5)2]nHet1, CO-Het1, CHO, COA, =S, =NH, =NA y/u =O (oxígeno del carbonilo), Het1 es un heterociclo saturado monocíclico con 1 a 2 átomos de N y/u O, que puede estar mono- o disustituido con A, OA, OH, Hal y/u =O (oxígeno del carbonilo), Hal es F, CI, Br o I, m es 0,1 o 2, n es 0,1, 2, 3 o 4, p es 2, 3, 4, 5 o 6, q es 1, 2, 3, 4 o 5, así como sus sales, tautomeros y estereoisomeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones. Son inhibidores de las tirosina quinasas, en especial de la Met-quinasa, y pueden utilizarse, por ejemplo, para el tratamiento de tumores. Procedimiento de preparacion, composiciones farmacéuticas y usos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009003954A DE102009003954A1 (de) | 2009-01-07 | 2009-01-07 | Pyridazinonderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075122A1 true AR075122A1 (es) | 2011-03-09 |
Family
ID=41719075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100014A AR075122A1 (es) | 2009-01-07 | 2010-01-06 | Derivados de piridazinona |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8853211B2 (es) |
| EP (1) | EP2373644B1 (es) |
| JP (1) | JP2012514613A (es) |
| KR (1) | KR101674695B1 (es) |
| CN (1) | CN102272125B (es) |
| AR (1) | AR075122A1 (es) |
| AU (1) | AU2009336852B2 (es) |
| BR (1) | BRPI0923913B1 (es) |
| CA (1) | CA2748911C (es) |
| CY (1) | CY1113698T1 (es) |
| DE (1) | DE102009003954A1 (es) |
| DK (1) | DK2373644T3 (es) |
| EA (1) | EA019322B1 (es) |
| ES (1) | ES2396301T3 (es) |
| HR (1) | HRP20120979T1 (es) |
| IL (1) | IL213828A (es) |
| MX (1) | MX2011007165A (es) |
| PL (1) | PL2373644T3 (es) |
| PT (1) | PT2373644E (es) |
| SG (1) | SG172421A1 (es) |
| SI (1) | SI2373644T1 (es) |
| SM (1) | SMT201300004B (es) |
| WO (1) | WO2010078910A1 (es) |
| ZA (1) | ZA201105780B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009004061A1 (de) * | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| CN102731409A (zh) * | 2011-04-08 | 2012-10-17 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物，其药物组合物、制备方法及用途 |
| JP6943857B2 (ja) | 2015-12-22 | 2021-10-06 | シンジェンタ パーティシペーションズ アーゲー | 有害生物防除活性ピラゾール誘導体 |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| KR102476708B1 (ko) | 2017-11-01 | 2022-12-09 | 삼성전자주식회사 | 광학 필터, 및 이를 포함하는 카메라 모듈 및 전자 장치 |
| KR102673362B1 (ko) * | 2018-03-27 | 2024-06-05 | 삼성전자주식회사 | 근적외선 흡수 필름, 광학 필터 및 전자 장치 |
| CN108752322A (zh) * | 2018-09-12 | 2018-11-06 | 广州新民培林医药科技有限公司 | 一种新型Tepotinib衍生物和制备方法及其在抗肿瘤药物中的应用 |
| ES2949871T3 (es) | 2019-04-11 | 2023-10-03 | Janssen Pharmaceutica Nv | Anillos de piridina que contienen derivados como inhibidores de MALT1 |
| CN115583939A (zh) * | 2022-11-04 | 2023-01-10 | 苏州莱安医药化学技术有限公司 | 一种特泊替尼中间体的合成方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| IL115889A0 (en) | 1994-11-14 | 1996-01-31 | Rohm & Haas | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AU738595B2 (en) | 1997-11-19 | 2001-09-20 | Kowa Co., Ltd. | Novel pyridazine derivatives and medicines containing the same as effective ingredients |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| HUP0401984A3 (en) | 2001-10-31 | 2005-06-28 | Merck Patent Gmbh | Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| BRPI0619424B1 (pt) | 2005-12-05 | 2022-02-08 | Pfizer Products Inc | Uso de inibidores c-met/hgfrs para a fabricação de medicamentos |
| DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| US8340070B2 (en) * | 2006-10-03 | 2012-12-25 | Qualcomm Incorporated | Resource partitioning for wireless communication systems |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007061963A1 (de) * | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
-
2009
- 2009-01-07 DE DE102009003954A patent/DE102009003954A1/de not_active Withdrawn
- 2009-12-10 DK DK09793467.3T patent/DK2373644T3/da active
- 2009-12-10 SI SI200930471T patent/SI2373644T1/sl unknown
- 2009-12-10 EA EA201101041A patent/EA019322B1/ru not_active IP Right Cessation
- 2009-12-10 CA CA2748911A patent/CA2748911C/en active Active
- 2009-12-10 EP EP09793467A patent/EP2373644B1/de active Active
- 2009-12-10 WO PCT/EP2009/008840 patent/WO2010078910A1/de not_active Ceased
- 2009-12-10 KR KR1020117017551A patent/KR101674695B1/ko not_active Expired - Fee Related
- 2009-12-10 PT PT97934673T patent/PT2373644E/pt unknown
- 2009-12-10 HR HRP20120979AT patent/HRP20120979T1/hr unknown
- 2009-12-10 MX MX2011007165A patent/MX2011007165A/es active IP Right Grant
- 2009-12-10 US US13/142,861 patent/US8853211B2/en active Active
- 2009-12-10 PL PL09793467T patent/PL2373644T3/pl unknown
- 2009-12-10 BR BRPI0923913-8A patent/BRPI0923913B1/pt not_active IP Right Cessation
- 2009-12-10 ES ES09793467T patent/ES2396301T3/es active Active
- 2009-12-10 JP JP2011544798A patent/JP2012514613A/ja active Pending
- 2009-12-10 SG SG2011047511A patent/SG172421A1/en unknown
- 2009-12-10 CN CN200980153447.XA patent/CN102272125B/zh not_active Expired - Fee Related
- 2009-12-10 AU AU2009336852A patent/AU2009336852B2/en not_active Ceased
-
2010
- 2010-01-06 AR ARP100100014A patent/AR075122A1/es active IP Right Grant
-
2011
- 2011-06-28 IL IL213828A patent/IL213828A/en not_active IP Right Cessation
- 2011-08-05 ZA ZA2011/05780A patent/ZA201105780B/en unknown
-
2012
- 2012-12-07 CY CY20121101192T patent/CY1113698T1/el unknown
-
2013
- 2013-01-09 SM SM201300004T patent/SMT201300004B/xx unknown
-
2014
- 2014-01-31 US US14/169,891 patent/US9376426B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075122A1 (es) | Derivados de piridazinona | |
| AR071208A1 (es) | Derivados de piridazinona | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| AR066543A1 (es) | Derivados de piridazinona | |
| AR073055A1 (es) | Derivados biciclicos de triazol | |
| AR057214A1 (es) | Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. | |
| AR076750A1 (es) | Derivados de 3-((1,2,3) triazol -4-il)- pirrolo (2,3-b) piridina | |
| AR066770A1 (es) | Derivados de piridazinona | |
| AR077567A1 (es) | Derivados de aminopiridina | |
| AR083670A1 (es) | DERIVADOS DE 7-([1,2,3]TRIAZOL-4-IL)-PIRROLO[2,3-b]PIRAZINA UTILES COMO INHIBIDORES DE LA PROLIFERACION CELULAR, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y PROCEDIMIENTO PARA PREPARARLOS | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR074688A1 (es) | Derivados de piridazinona, procedimiento para prepararlos, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. | |
| AR072792A1 (es) | DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS | |
| AR067081A1 (es) | Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales. | |
| AR068659A1 (es) | Derivados de imidazol inhibidores de autotaxina | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR082109A1 (es) | Derivados de bipiridilo | |
| AR068872A1 (es) | 5- ciano- tienopiridinas. procesos de obtencion y composiciones farmaceuticas. | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| AR076006A1 (es) | Compuestos heterociclicos inhibidores de autotaxina utiles para el tratamiento de tumores, proceso para prepararlos y medicamentos que los contienen. | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR068657A1 (es) | Derivados de piperidina y piperazina | |
| AR077488A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de autotaxina, medicamentos que los contienen y uso de los mismos para el tratamiento y/o prevencion de cancer y enfermedades tumorales. | |
| AR067506A1 (es) | Derivados de quinazolinamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FG | Grant, registration |